SCHEMBL3124091

SCHEMBL3124091

COc1ccc(C(=O)Cl)c(O)c1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.72
RAB9A P51151 5/20 0.72
CYP3A4 P08684 6/20 0.70
HPGD P15428 5/20 0.70
ALDH1A1 P00352 5/20 0.70
MAPK1 P28482 4/20 0.70
LMNA P02545 5/20 0.62
CYP2C19 P33261 3/20 0.62
CYP1A2 P05177 2/20 0.62
PGR P06401 2/20 0.62
SLC6A2 P23975 2/20 0.62
ALOX15 P16050 2/20 0.62
ADORA3 P0DMS8 1/20 0.62
AR P10275 1/20 0.62
CHRM1 P11229 1/20 0.62
TBXA2R P21731 1/20 0.62
ADRA1A P35348 1/20 0.62
HIF1A Q16665 1/20 0.62
CYP2D6 P10635 1/20 0.60
PDE4A P27815 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4954916 0.85 NPC1 (0.56) NPC1RAB9ACYP3A4HPGDALDH1A1
SCHEMBL29365072 0.84 NPC1 (1.00) NPC1RAB9ACYP3A4HPGDALDH1A1
SCHEMBL38652 0.84 NPC1 (1.00) NPC1RAB9ACYP3A4HPGDALDH1A1
SCHEMBL1514997 0.84 NPC1 (1.00) NPC1RAB9ACYP3A4HPGDALDH1A1
SCHEMBL11197823 0.84 NPC1 (0.55) NPC1RAB9ACYP3A4HPGDALDH1A1
SCHEMBL93206 0.83 NPC1 (0.89) NPC1RAB9ACYP3A4HPGDALDH1A1
SCHEMBL29419872 0.83 NPC1 (0.89) NPC1RAB9ACYP3A4HPGDALDH1A1
SCHEMBL1348833 0.83 NPC1 (0.89) NPC1RAB9ACYP3A4HPGDALDH1A1
SCHEMBL30900821 0.83 NPC1 (0.89) NPC1RAB9ACYP3A4HPGDALDH1A1
SCHEMBL6851855 0.82 NPC1 (0.75) NPC1RAB9ACYP3A4HPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110357824-A [3,5- di-substituted-phenyl -1- (1,2,4- triazol radical)] benzene sulfonic derivative and preparation method and application 中山大学 2019-10-22 CN disclosed
US-7763614-B2 Isoquinoline potassium channel inhibitors MERCK SHARP & DOHME CORP. (US) 2010-07-27 US disclosed
US-7763614-B2 Isoquinoline potassium channel inhibitors MERCK SHARP & DOHME CORP. (US) 2010-07-27 US disclosed
US-7763614-B2 Isoquinoline potassium channel inhibitors MERCK SHARP & DOHME CORP. (US) 2010-07-27 US disclosed
US-7691879-B2 Isoquinoline potassium channel inhibitors MERCK SHARP & DOHME CORP. (US) 2010-04-06 US disclosed
WO-2010018435-A1 AMIDE GLYCOSIDES HETERO RESEARCH FOUNDATION (IN) 2010-02-18 WO disclosed
CN-100475776-C Amino acid diamides in non alpha position useful as adjuvants for the administration of active biological agents ROVI LAB FARMACEUT SA (ES) 2009-04-08 CN disclosed
US-7462735-B2 Amino acid diamides in non α position which are useful as adjuvants for administration of biological active agents LABORATORIOS FARMACEUTICOS ROVI, S.A. (ES) 2008-12-09 US disclosed
EP-1667981-A4 ISOQUINOLINE POTASSIUM CHANNEL INHIBITORS MERCK & CO INC (US) 2008-08-13 EP disclosed
US-20070191302-A1 AMINO ACID DIAMIDES IN NON ALPHA POSITION WHICH ARE USEFUL AS ADJUVANTS FOR ADMINISTRATION OF BIOLOGICAL ACTIVE AGENTS LABORATORIOS FARMACEUTICOS ROVI S.A. (ES) 2007-08-16 US disclosed
US-20060276450-A1 Isoquinoline potassium channel inhibitors MERCK SHARP & DOHME CORP. 2006-12-07 US disclosed
CN-1856475-A Isoquinoline potassium channel inhibitors MERCK & CO INC (US) 2006-11-01 CN disclosed
CN-1856477-A Isoquinoline potassium channel inhibitors MERCK & CO INC (US) 2006-11-01 CN disclosed
CN-1829682-A Amino acid diamides in non-alpha positions useful as adjuvants for the administration of biologically active agents ROVI LAB FARMACEUT SA (ES) 2006-09-06 CN disclosed
EP-1667981-A1 ISOQUINOLINE POTASSIUM CHANNEL INHIBITORS Merck & Co., Inc. (US) 2006-06-14 EP disclosed
EP-1667979-A2 ISOQUINOLINE POTASSIUM CHANNEL INHIBITORS Merck & Co., Inc. (US) 2006-06-14 EP disclosed
EP-1652836-A1 AMINO ACID DIAMIDES IN NON ALPHA POSITION USEFUL AS ADJUVANTS FOR THE ADMINISTRATION OF ACTIVE BIOLOGICAL AGENTS LABORATORIOS FARMACEUTICOS ROVI, S.A. (ES) 2006-05-03 EP disclosed
US-20050124664-A1 Urea thiadiazole inhibitors of plasminogen activator inhibior-1 BRISTOL-MYERS SQUIBB CO. 2005-06-09 US disclosed
WO-2005030729-A1 ISOQUINOLINE POTASSIUM CHANNEL INHIBITORS MERCK & CO., INC. (US) 2005-04-07 WO disclosed
WO-2005030130-A2 ISOQUINOLINE POTASSIUM CHANNEL INHIBITORS MERCK & CO., INC. (US) 2005-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276450-A1 Isoquinoline potassium channel inhibitors KCNQ1, KCNQ2, KCNJ2 NPC1 484/4885RAB9A 2350/4885CYP3A4 1201/4885
US-20050124664-A1 Urea thiadiazole inhibitors of plasminogen activator inhibior-1 SERPINE1, SERPINC1, SERPINB1 NPC1 2401/4885RAB9A 3129/4885CYP3A4 369/4885
US-20070191302-A1 AMINO ACID DIAMIDES IN NON ALPHA POSITION WHICH ARE USEFUL AS ADJUVANTS FOR ADMINISTRATION OF BIOLOGICAL ACTIVE AGENTS NOS1, NOS3, ARG1 NPC1 4652/4885RAB9A 3800/4885CYP3A4 1165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.